ABSTRACT
Thrombophilia includes multiple inherited and acquired risk factors that determine a shift in the balance of procoagulant and anticoagulant factors promoting hypercoagulability, which is associated with an increased risk of venous thromboembolism (VTE). VTE is characterized by more common clinical manifestations, such as deep vein thrombosis of the lower limbs or pulmonary embolism, and less common clinical manifestations affecting cerebral, splanchnic, upper limbs, and retinal veins. The role of inherited thrombophilia in the pathogenesis of VTE at unusual sites is better established in cerebral vein thrombosis, but its role is less clear in splanchnic, upper limbs, and retinal vein thrombosis, in which acquired risk factors such as malignancy, central venous catheters, or systemic diseases also are frequently involved. The complex interactions between different inherited and acquired thrombophilic risk factors and their relationship with endothelium may be considered the pathophysiologic key of underlying phenotypic manifestations of thrombosis. The understanding of these mechanisms might facilitate diagnosis with appropriate investigations and improve therapeutic decision making.
KEYWORDS
Thrombophilia - thrombosis of the upper extremities - retinal vein occlusion - cerebral vein thrombosis - splanchnic vein thrombosis
REFERENCES
-
1
Infante-Rivard C, David M, Gauthier R, Rivard G E.
Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case-control study.
N Engl J Med.
1991;
325
1063-1066
-
2
De Stefano V, Fiorini A, Rossi E et al..
Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.
J Thromb Haemost.
2007;
5
708-714
-
3
Primignani M, Martinelli I, Bucciarelli P et al..
Risk factors for thrombophilia in extrahepatic portal vein obstruction.
Hepatology.
2005;
41
603-608
-
4
Dentali F, Crowther M, Ageno W.
Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis.
Blood.
2006;
107
2766-2773
-
5
Rosenberg R D, Aird W C.
Vascular-bed-specific hemostasis and hypercoagulable states.
N Engl J Med.
1999;
340
1555-1564
-
6
Joffe H V, Kucher N, Tapson V F, Goldhaber S Z.
Upper-extremity deep vein thrombosis: a prospective registry of 592 patients.
Circulation.
2004;
110
1605-1611
-
7
Hill S L, Berry R E.
Subclavian vein thrombosis: a continuing challenge.
Surgery.
1990;
108
1-9
-
8
Mustafa S, Stein P D, Patel K C, Otten T R, Holmes R, Silbergleit A.
Upper extremity deep venous thrombosis.
Chest.
2003;
123
1953-1956
-
9
Blom J W, Doggen C J, Osanto S, Rosendaal F R.
Old and new risk factors for upper extremity deep venous thrombosis.
J Thromb Haemost.
2005;
3
2471-2478
-
10
Martinelli I, Battaglioli T, Bucciarelli P, Passamonti S M, Mannucci P M.
Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities.
Circulation.
2004;
110
566-570
-
11
Nemcek Jr A A.
Upper extremity deep venous thrombosis: interventional management.
Tech Vasc Interv Radiol.
2004;
7
86-90
-
12
Zell L, Kindermann W, Marschall F, Scheffler P, Gross J, Buchter A.
Paget-Schroetter syndrome in sports activities-case study and literature review.
Angiology.
2001;
52
337-342
-
13
Hendler M F, Meschengieser S S, Blanco A N et al..
Primary upper-extremity deep vein thrombosis: high prevalence of thrombophilic defects.
Am J Hematol.
2004;
76
330-337
-
14
Heron E, Lozinguez O, AlhencGelas M, Emmerich J, Fiessinger J N.
Hypercoagulable states in primary upper-extremity deep vein thrombosis.
Arch Intern Med.
2000;
160
382-386
-
15
Vaya A, Mira Y, Mateo J et al..
Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk.
Thromb Haemost.
2003;
89
452-457
-
16
Girolami A, Prandoni P, Zanon E, Bagatella P, Girolami B.
Venous thromboses of upper limbs are more frequently associated with occult cancer as compared with those of lower limbs.
Blood Coagul Fibrinolysis.
1999;
10
455-457
-
17
Hingorani A, Ascher E, Markevich N et al..
Risk factors for mortality in patients with upper extremity and internal jugular deep venous thrombosis.
J Vasc Surg.
2005;
41
476-478
-
18
Marinella M A, Kathula S K, Markert R J.
Spectrum of upper-extremity deep venous thrombosis in a community teaching hospital.
Heart Lung.
2000;
29
113-117
-
19
Schmittling Z C, McLafferty R B, Bohannon W T, Ramsey D E, Hodgson K J.
Characterization and probability of upper extremity deep venous thrombosis.
Ann Vasc Surg.
2004;
18
552-557
-
20
Van Rooden C J, Rosendaal F R, Meinders A E, Van Oostayen J A, Van Der Meer F J, Huisman M V.
The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis.
Haematologica.
2004;
89
201-206
-
21
Chan W S, Ginsberg J S.
A review of upper extremity deep vein thrombosis in pregnancy: unmasking the ‘ART' behind the clot.
J Thromb Haemost.
2006;
4
1673-1677
-
22
David R, Zangwill L, Badarna M, Yassur Y.
Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure.
Ophthalmologica.
1988;
197
69-74
-
23
Hayreh S S, Zimmerman M B, Podhajsky P.
Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics.
Am J Ophthalmol.
1994;
117
429-441
-
24
Prisco D, Marcucci R, Bertini L, Gori A M.
Cardiovascular and thrombophilic risk factors for central retinal vein occlusion.
Eur J Intern Med.
2002;
13
163-169
-
25
Hayreh S S, Zimmerman B, McCarthy M J, Podhajsky P.
Systemic diseases associated with various types of retinal vein occlusion.
Am J Ophthalmol.
2001;
131
61-77
-
26
Mitchell P, Smith W, Chang A.
Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study.
Arch Ophthalmol.
1996;
114
1243-1247
-
27
Dodson P M, Galton D J, Hamilton A M, Blach R K.
Retinal vein occlusion and the prevalence of lipoprotein abnormalities.
Br J Ophthalmol.
1982;
66
161-164
-
28
Quinlan P M, Elman M J, Bhatt A K, Mardesich P, Enger C.
The natural course of central retinal vein occlusion.
Am J Ophthalmol.
1990;
110
118-123
-
29
Cugati S, Wang J J, Rochtchina E, Mitchell P.
Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study.
Arch Ophthalmol.
2006;
124
726-732
-
30
Janssen M C, den Heijer M, Cruysberg J R, Wollersheim H, Bredie S J.
Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors.
Thromb Haemost.
2005;
93
1021-1026
-
31
Arsene S, Delahousse B, Regina S, Le Lez M L, Pisella P J, Gruel Y.
Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age.
Thromb Haemost.
2005;
94
101-106
-
32
Chua B, Kifley A, Wong T Y, Mitchell P.
Homocysteine and retinal vein occlusion: a population-based study.
Am J Ophthalmol.
2005;
139
181-182
-
33
McGimpsey S J, Woodside J V, Bamford L et al..
Retinal vein occlusion, homocysteine, and methylene tetrahydrofolate reductase genotype.
Invest Ophthalmol Vis Sci.
2005;
46
4712-4716
-
34
Pinna A, Carru C, Zinellu A, Dore S, Deiana L, Carta F.
Plasma homocysteine and cysteine levels in retinal vein occlusion.
Invest Ophthalmol Vis Sci.
2006;
47
4067-4071
-
35
Cugati S, Wang J J, Knudtson M D et al..
Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts.
Ophthalmology.
2007;
114
520-524
-
36
Ameri A, Bousser M G.
Cerebral venous thrombosis.
Neurol Clin.
1992;
10
87-111
-
37
Gates P C.
Cerebral venous thrombosis. A retrospective review.
Aust N Z J Med.
1986;
16
766-770
-
38
Ferro J M, Canhao P, Stam J, Bousser M G, Barinagarrementeria F.
Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).
Stroke.
2004;
35
664-670
-
39
de Bruijn S F, Stam J.
Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis.
Stroke.
1999;
30
484-488
-
40
Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci P M.
Hyperhomocysteinemia in cerebral vein thrombosis.
Blood.
2003;
102
1363-1366
-
41
Bombeli T, Basic A, Fehr J.
Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems.
Am J Hematol.
2002;
70
126-132
-
42
Christopher R, Nagaraja D, Dixit N S, Narayanan C P.
Anticardiolipin antibodies: a study in cerebral venous thrombosis.
Acta Neurol Scand.
1999;
99
121-124
-
43
Gadelha T, Andre C, Juca A A, Nucci M.
Prothrombin 20210A and oral contraceptive use as risk factors for cerebral venous thrombosis.
Cerebrovasc Dis.
2005;
19
49-52
-
44
Bugnicourt J M, Roussel B, Tramier B, Lamy C, Godefroy O.
Cerebral venous thrombosis and plasma concentrations of factor VIII and von Willebrand factor: a case-control study.
J Neurol Neurosurg Psychiatry.
2007;
78
699-701
-
45
Lichy C, Dong-Si T, Reuner K et al..
Risk of cerebral venous thrombosis and novel gene polymorphisms of the coagulation and fibrinolytic systems.
J Neurol.
2006;
253
316-320
-
46
Kumar S, Sarr M G, Kamath P S.
Mesenteric venous thrombosis.
N Engl J Med.
2001;
345
1683-1688
-
47
Valla D C, Condat B.
Portal vein thrombosis in adults: pathophysiology, pathogenesis and management.
J Hepatol.
2000;
32
865-871
-
48
Janssen H L, Meinardi J R, Vleggaar F P et al..
Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study.
Blood.
2000;
96
2364-2368
-
49
Amitrano L, Brancaccio V, Guardascione M A et al..
High prevalence of thrombophilic genotypes in patients with acute mesenteric vein thrombosis.
Am J Gastroenterol.
2001;
96
146-149
Federico LussanaM.D.
Department of Vascular Medicine, Academic Medical Center, University of Amsterdam
Meibergdreef 9 1105 AZ Amsterdam, The Netherlands
Email: federico.lussana@ao-sanpaolo.it
